Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262779 · ClinicalTrials.gov registry record · Phase 2
Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT03262779 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 20 participants.
The verdict
NCT03262779, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The investigators propose a trial to evaluate if the addition of ipilimumab to nivolumab after primary or acquired resistance to anti- programmed death 1 (PD-1) axis therapy can lead to objective radiographic tumor regression.
Interventions
- BIOLOGICAL combination nivolumab and ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-07-20 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03262779
The ClinicalTrials.gov registry entry for NCT03262779 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which combination nivolumab and ipilimumab is the first listed.
NCT03262779 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03262779 about?
NCT03262779 is a clinical study titled "Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.". The investigators propose a trial to evaluate if the addition of ipilimumab to nivolumab after primary or acquired resistance to anti- programmed death 1 (PD-1) axis therapy can lead to objective radiographic tumor regression.
What is the current status of trial NCT03262779?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2017-07-20. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT03262779?
The interventions under investigation include: combination nivolumab and ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03262779?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.